Breaking News, Collaborations & Alliances

FDA Approves Biosimilar Referencing Stelara Injection

The approval of STARJEMZA was based on a comprehensive analytical, non-clinical, and clinical data package submitted by Bio-Thera to the FDA.

Author Image

By: Charlie Sternberg

Associate Editor

The U.S. Food and Drug Administration (FDA) has approved STARJEMZA (ustekinumab-hmny) Injection, a biosimilar referencing Stelara (ustekinumab) Injection. Bio-Thera and Hikma entered into a license and commercialization agreement for STARJEMZA in August 2021. Under the terms of the agreement, Bio-Thera is responsible for the development and manufacturing of the product. Hikma is responsible for the commercialization of STARJEMZA in the United States. “The approval of STARJEMZA is ano...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters